Attention Deficit Hyperactivity Disorder, Dyslexia
Conditions
Brief summary
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
Interventions
Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
oral, daily, for 16 weeks
Sponsors
Study design
Eligibility
Inclusion criteria
* patients must meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for Attention-Deficit/Hyperactivity Disorder (ADHD) * patients must achieve a score of 80 or more on the Full Scale Intelligence Quotient * child or adolescent patients must be 10 to 16 years old * must be able to communicate in English * must be able to swallow capsules * be reliable to keep appointments for clinic visits and all related tests
Exclusion criteria
* patients who weigh less than 25 Kg or greater than 70 Kg * patients with a history of alcohol or drug abuse on a repeated basis within the past 3 months * patients with documented history of autism, Asperger's syndrome or pervasive developmental disorder * females who are pregnant or breastfeeding * patients with a history of severe allergy to more than one class of medications * patients with documented history of bipolar I or bipolar II disorder, or psychosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total Score - Parent Version at Week 16 Endpoint | Baseline, 16 weeks | Measures the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD). Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0-54. Least Square mean of change from baseline in ADHDRS is from a restricted maximum likelihood-based, mixed model repeated measures analysis which includes the effects of treatment, investigative site, baseline, visit, treatment-by-visit interaction, and baseline-by-visit interaction. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint | Baseline, 16 weeks | The ADHDRS-IV-Teacher is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3=severe (very often). Hyperactivity-impulsivity scores range from 0-27, and inattention scores range from 0-27. Total scores range from 0-54. Higher scores indicate higher impairment. |
| Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Baseline, 16 weeks | The Woodcock Johnson Tests of Achievement has a Standard Battery (Tests 1-12) of a broad set of scores and an Extended Battery (Tests 13-22) on specific academic strengths and weaknesses. Tests associated with reading skills (1, 2, 7, 9, 13, 17, 20) were administered. Scores for each individual test can range from 0 to over 200 where anything 69 and below is very low and anything 131 and above is very superior. Higher scores indicate better reading skills. |
| Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Baseline, 16 weeks | The CTOPP assesses phonological awareness, phonological memory, and rapid naming and is appropriate for ages 7 to 24. The test contains six core subtests. The composite scores are 1) Phonological Awareness, comprised of the standard scores of the Elision and Blending Words; 2) Phonological Memory, comprised of standard scores for Memory for Digits and Non-word Repetition; and 3) Rapid Naming, comprised of standard scores for Rapid Digit Naming and Rapid Letter Naming. Standard scores range from 1-20, and composite scores range from 35-165. Higher scores are better. |
| Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Baseline, 16 weeks | The GORT-4 is a norm-referenced test of oral reading rate, accuracy, fluency, and comprehension valid for individuals aged 6 to 18 years old. The test has two parallel forms, Form A and Form B, that are administered in an alternating fashion (e.g. Week 0-Form A, Week 16-Form B, Week 32-Form A.) with each containing 14 separate stories and 5 multiple-choice comprehension questions for each story. GORT-4 yields the following scores: rate, accuracy, fluency, comprehension, and overall reading ability. Standard scores range from 1-20. Higher scores indicate better reading skills. |
| Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint | Baseline, 16 weeks | The TOWRE is a measure of an individual's ability to pronounce printed words accurately and fluently and is appropriate for individuals aged 6 to 24 years old. The TOWRE contains two subtests: Sight Word Efficiency (SWE) which assesses the number of real printed words that can be accurately identified within 45 seconds and Phonemic Decoding Efficiency (PDE) which measures the number of pronounceable printed non-words that can be accurately decoded within 45 seconds. Scores range from 45-146. Higher scores indicate higher reading proficiency. |
| Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Baseline, 16 weeks | WMTB-C is assessment of working memory capacities, consisting of 9 subtests (Trials Correct Scores \[Range from 55-145\], Higher scores are better) reflecting 3 main components of working memory: central executive (CE) control/regulation of working memory (Backward Digit Recall, Listening Recall, Counting Recall); phonological loop (PL) responsible for holding verbal information for short periods (Digit Recall, Word List Matching, Word List Recall, Non-word List Recall); and visuo-spatial sketchpad (VSSP) which holds information in visual and spatial form (Block Recall, Mazes Memory). |
| Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint | Baseline, 16 weeks | LPS-C is a short (24 item, 0-3 points per item) parent-rated scale that is designed to assess changes in adaptive functioning related to treatment for ADHD. This scale measures improvements in social, emotional, cognitive, educational, and affiliative (family, friends) functioning, which indirectly reflect improvements in executive functioning. Happy/social subscores range from 0-18, and self-control subscores range from 0-54. Total scores range from 0-72. Higher scores are better for LPS. |
| Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint | Baseline, 16 weeks | The K-SCT rating scale contains 3 components: Youth, Parent, and Teacher ratings. It queries 17 candidate SCT symptoms, such as daydreams, lost in a fog, sluggish/drowsy. Scores range from 0-51. Lower scores indicate less sluggish. |
| Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Baseline, 16 weeks | The MSCS is an overall assessment of self concept or an individual measure of any of the six scaled dimensions of self concept: Social, Competence, Affect, Academic, Family, and Physical. Standard scores range from 45-145. Higher scores are better (indicate higher self concept). |
| Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint | Baseline, 16 weeks | The ADHDRS-IV-Parent is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3=severe (very often). Hyperactivity-impulsivity scores range 0-27, and inattention scores range 0-27. Total scores range from 0-54. Higher scores indicate higher impairment. |
| Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 Endpoint | Baseline, 32 weeks | The ADHDRS-IV-Teacher is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3 =severe (very often). Hyperactivity-impulsivity scores range from 0-27, and inattention scores range from 0-27. Total scores range from 0-54. Higher scores indicate higher impairment. |
| Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Baseline, 32 weeks | The Woodcock Johnson Tests of Achievement has a Standard Battery (Tests 1-12) of a broad set of scores and an Extended Battery (Tests 13-22) on specific academic strengths and weaknesses. Tests associated with reading skills (1, 2, 7, 9, 13, 17, 20) were administered. Scores for each individual test can range from 0 to over 200 where anything 69 and below is very low and anything 131 and above is very superior. Higher scores indicate better reading skills. |
| Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Baseline, 32 weeks | The CTOPP assesses phonological awareness, phonological memory, and rapid naming and is appropriate for ages 7 to 24. The test contains six core subtests. The composite scores are 1) Phonological Awareness, comprised of the standard scores of the Elision and Blending Words; 2) Phonological Memory, comprised of standard scores for Memory for Digits and Non-word Repetition; and 3) Rapid Naming, comprised of standard scores for Rapid Digit Naming and Rapid Letter Naming. Standard scores range from 1-20, and composite scores range from 35-165. Higher scores are better. |
| Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint | Baseline, 32 weeks | The GORT-4 is a norm-referenced test of oral reading rate, accuracy, fluency, and comprehension valid for individuals aged 6 to 18 years old. The test has two parallel forms, Form A and Form B, that are administered in an alternating fashion (e.g. Week 0-Form A, Week 16-Form B, Week 32-Form A.) with each containing 14 separate stories and 5 multiple-choice comprehension questions for each story. GORT-4 yields the following scores: rate, accuracy, fluency, comprehension, and overall reading ability. Standard scores range from 1-20. Higher scores indicate better reading skills. |
| Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 Endpoint | Baseline, 32 weeks | The TOWRE is a measure of an individual's ability to pronounce printed words accurately and fluently and is appropriate for individuals aged 6 to 24 years old. The TOWRE contains two subtests: Sight Word Efficiency (SWE) which assesses the number of real printed words that can be accurately identified within 45 seconds and Phonemic Decoding Efficiency (PDE) which measures the number of pronounceable printed non-words that can be accurately decoded within 45 seconds. Scores range from 45-146. Higher scores indicate higher reading proficiency. |
| Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Baseline, 32 weeks | WMTB-C is assessment of working memory capacities, consisting of 9 subtests (Trials Correct Scores \[Range from 55-145\], Higher scores are better) reflecting 3 main components of working memory: central executive (CE) control/regulation of working memory (Backward Digit Recall, Listening Recall, Counting Recall); phonological loop (PL) responsible for holding verbal information for short periods (Digit Recall, Word List Matching, Word List Recall, Non-word List Recall); and visuo-spatial sketchpad (VSSP) which holds information in visual and spatial form (Block Recall, Mazes Memory). |
| Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 Endpoint | Baseline, 32 weeks | LPS-C is a short (24 item, 0-3 points per item) parent-rated scale that is designed to assess changes in adaptive functioning related to treatment for ADHD. This scale measures improvements in social, emotional, cognitive, educational, and affiliative (family, friends) functioning, which indirectly reflect improvements in executive functioning. Happy/social subscores range from 0-18, and self-control subscores range from 0-54. Total scores range from 0-72. Higher scores are better for LPS. |
| Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 Endpoint | Baseline, 32 weeks | The K-SCT rating scale contains 3 components: Youth, Parent, and Teacher ratings. It queries 17 candidate SCT symptoms, such as daydreams, lost in a fog, sluggish/drowsy. Scores range from 0-51. Lower scores indicate less sluggish. |
| Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Baseline, 32 weeks | The MSCS is an overall assessment of self concept or an individual measure of any of the six scaled dimensions of self concept: Social, Competence, Affect, Academic, Family, and Physical. Standard scores range from 45-145. Higher scores are better (indicate higher self concept). |
| Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 Endpoint | Baseline, 32 weeks | The ADHDRS-IV-parent is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3 =severe (very often). Hyperactivity-impulsivity scores range from 0-27, and inattention scores range from 0-27. Total scores range from 0-54. Higher scores indicate higher impairment. |
Countries
United States
Participant flow
Pre-assignment details
The study comprised a 16-week placebo-controlled, double-blind acute phase and followed by an optional 16-week open-label in which all participants were treated with Atomoxetine.
Participants by arm
| Arm | Count |
|---|---|
| Atomoxetine/Atomoxetine Participants were assigned to Atomoxetine treatment in both acute and open-label phase
Atomoxetine was administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks. All eligible participants who completed the double-blind acute phase had the option of participating in a 16-week open-label extension period in which participants were treated with Atomoxetine | 120 |
| Placebo/Atomoxetine Participants were assigned to placebo in acute phase and Atomoxetine in open-label phase.
Placebo was packaged in the same way as Atomoxetine, and administered orally once daily in the morning for 16 weeks. All eligible participants who completed the double-blind acute phase had the option of participating in a 16-week open-label extension period in which participants were treated with Atomoxetine | 89 |
| Total | 209 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Acute Phase | Adverse Event | 9 | 2 |
| Acute Phase | Entry Criteria Not Met | 1 | 1 |
| Acute Phase | Lack of Efficacy | 1 | 2 |
| Acute Phase | Lost to Follow-up | 9 | 3 |
| Acute Phase | Parent/Caregiver Decision | 6 | 4 |
| Acute Phase | Protocol Violation | 5 | 1 |
| Acute Phase | Withdrawal by Subject | 3 | 3 |
| Open-Label Phase | Adverse Event | 1 | 5 |
| Open-Label Phase | Lost to Follow-up | 4 | 1 |
| Open-Label Phase | Parent/Caregiver Decision | 1 | 2 |
| Open-Label Phase | Protocol Violation | 2 | 2 |
| Open-Label Phase | Withdrawal by Subject | 2 | 2 |
Baseline characteristics
| Characteristic | Placebo/Atomoxetine | Total | Atomoxetine/Atomoxetine |
|---|---|---|---|
| Age Continuous | 12.44 years STANDARD_DEVIATION 1.9 | 12.32 years STANDARD_DEVIATION 1.8 | 12.24 years STANDARD_DEVIATION 1.72 |
| Race/Ethnicity, Customized African | 11 participants | 24 participants | 13 participants |
| Race/Ethnicity, Customized Caucasian | 66 participants | 152 participants | 86 participants |
| Race/Ethnicity, Customized East Asian | 1 participants | 3 participants | 2 participants |
| Race/Ethnicity, Customized Hispanic | 11 participants | 29 participants | 18 participants |
| Race/Ethnicity, Customized West Asian | 0 participants | 1 participants | 1 participants |
| Region of Enrollment United States | 89 participants | 209 participants | 120 participants |
| Sex: Female, Male Female | 34 Participants | 80 Participants | 46 Participants |
| Sex: Female, Male Male | 55 Participants | 129 Participants | 74 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 108 / 120 | 71 / 89 |
| serious Total, serious adverse events | 1 / 120 | 0 / 89 |
Outcome results
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total Score - Parent Version at Week 16 Endpoint
Measures the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD). Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Total scores range from 0-54. Least Square mean of change from baseline in ADHDRS is from a restricted maximum likelihood-based, mixed model repeated measures analysis which includes the effects of treatment, investigative site, baseline, visit, treatment-by-visit interaction, and baseline-by-visit interaction.
Time frame: Baseline, 16 weeks
Population: All randomized participants with a baseline and at least one post-baseline result.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total Score - Parent Version at Week 16 Endpoint | -20.01 units on a scale | Standard Error 1.45 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total Score - Parent Version at Week 16 Endpoint | -12.27 units on a scale | Standard Error 1.41 |
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint
The ADHDRS-IV-Parent is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3=severe (very often). Hyperactivity-impulsivity scores range 0-27, and inattention scores range 0-27. Total scores range from 0-54. Higher scores indicate higher impairment.
Time frame: Baseline, 16 weeks
Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint | Inattention Score | -10.64 units on a scale | Standard Deviation 7.59 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint | Hyperactivity-Impulsivity Score | -8.23 units on a scale | Standard Deviation 5.9 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint | Total Score | -18.87 units on a scale | Standard Deviation 11.68 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint | Inattention Score | -7.79 units on a scale | Standard Deviation 6.52 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint | Hyperactivity-Impulsivity Score | -5.18 units on a scale | Standard Deviation 6.01 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint | Total Score | -12.98 units on a scale | Standard Deviation 10.75 |
| ADHD Alone: Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint | Hyperactivity-Impulsivity Score | -6.26 units on a scale | Standard Deviation 5.1 |
| ADHD Alone: Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint | Total Score | -16.59 units on a scale | Standard Deviation 11.31 |
| ADHD Alone: Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 16 Endpoint | Inattention Score | -10.33 units on a scale | Standard Deviation 7.95 |
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 Endpoint
The ADHDRS-IV-parent is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3 =severe (very often). Hyperactivity-impulsivity scores range from 0-27, and inattention scores range from 0-27. Total scores range from 0-54. Higher scores indicate higher impairment.
Time frame: Baseline, 32 weeks
Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 Endpoint | Hyperactivity-Impulsivity Score | -9.8 units on a scale | Standard Deviation 6.17 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 Endpoint | Inattention Score | -13.84 units on a scale | Standard Deviation 6.56 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 Endpoint | Total Score | -23.64 units on a scale | Standard Deviation 10.43 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 Endpoint | Hyperactivity-Impulsivity Score | -8.29 units on a scale | Standard Deviation 4.61 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 Endpoint | Inattention Score | -14.33 units on a scale | Standard Deviation 7.16 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Parent Version at Week 32 Endpoint | Total Score | -22.62 units on a scale | Standard Deviation 9.07 |
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint
The ADHDRS-IV-Teacher is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3=severe (very often). Hyperactivity-impulsivity scores range from 0-27, and inattention scores range from 0-27. Total scores range from 0-54. Higher scores indicate higher impairment.
Time frame: Baseline, 16 weeks
Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint | Hyperactivity-Impulsivity Score | -2.71 units on a scale | Standard Deviation 3.98 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint | Total Score | -7.19 units on a scale | Standard Deviation 6.83 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint | Inattention Score | -4.48 units on a scale | Standard Deviation 5.17 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint | Hyperactivity-Impulsivity Score | -1.99 units on a scale | Standard Deviation 6.54 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint | Inattention Score | -0.99 units on a scale | Standard Deviation 5.33 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint | Total Score | -2.98 units on a scale | Standard Deviation 10.83 |
| ADHD Alone: Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint | Total Score | -3.09 units on a scale | Standard Deviation 9.21 |
| ADHD Alone: Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint | Inattention Score | -2.27 units on a scale | Standard Deviation 5.24 |
| ADHD Alone: Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 16 Endpoint | Hyperactivity-Impulsivity Score | -0.82 units on a scale | Standard Deviation 4.92 |
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 Endpoint
The ADHDRS-IV-Teacher is an 18-item scale with 1 item for each of the 18 symptoms contained in the DSM-IV diagnosis of ADHD. Each item is scored on a 0 to 3 scale: 0=none (never or rarely); 1=mild (sometimes); 2=moderate (often); 3 =severe (very often). Hyperactivity-impulsivity scores range from 0-27, and inattention scores range from 0-27. Total scores range from 0-54. Higher scores indicate higher impairment.
Time frame: Baseline, 32 weeks
Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 Endpoint | Hyperactivity-Impulsivity Score | -1.87 units | Standard Deviation 4.8 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 Endpoint | Inattention Score | -4.28 units | Standard Deviation 6.08 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 Endpoint | Total Score | -6.15 units | Standard Deviation 8.51 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 Endpoint | Hyperactivity-Impulsivity Score | -2.89 units | Standard Deviation 4.48 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 Endpoint | Inattention Score | -4.19 units | Standard Deviation 4.11 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHDRS) Total and Subscores - Teacher Version at Week 32 Endpoint | Total Score | -7.08 units | Standard Deviation 7.34 |
Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint
The CTOPP assesses phonological awareness, phonological memory, and rapid naming and is appropriate for ages 7 to 24. The test contains six core subtests. The composite scores are 1) Phonological Awareness, comprised of the standard scores of the Elision and Blending Words; 2) Phonological Memory, comprised of standard scores for Memory for Digits and Non-word Repetition; and 3) Rapid Naming, comprised of standard scores for Rapid Digit Naming and Rapid Letter Naming. Standard scores range from 1-20, and composite scores range from 35-165. Higher scores are better.
Time frame: Baseline, 16 weeks
Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Non-word Repetition | 0.57 units on a scale | Standard Deviation 1.79 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Rapid Naming | 1.06 units on a scale | Standard Deviation 11 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Phonological Memory | 2.22 units on a scale | Standard Deviation 10.61 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Phonological Awareness | 5.20 units on a scale | Standard Deviation 9.49 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Blending Words | 0.96 units on a scale | Standard Deviation 1.9 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Rapid Letter Naming | 0.31 units on a scale | Standard Deviation 1.76 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Memory for Digits | 0.47 units on a scale | Standard Deviation 2.16 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Elision | 0.88 units on a scale | Standard Deviation 2.18 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Rapid Digit Naming | 0.26 units on a scale | Standard Deviation 2.06 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Phonological Awareness | 2.00 units on a scale | Standard Deviation 9.34 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Blending Words | 0.95 units on a scale | Standard Deviation 1.97 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Elision | -0.24 units on a scale | Standard Deviation 2.34 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Memory for Digits | 0.13 units on a scale | Standard Deviation 1.76 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Non-word Repetition | 0.51 units on a scale | Standard Deviation 2 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Phonological Memory | 0.96 units on a scale | Standard Deviation 10.16 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Rapid Digit Naming | 0.16 units on a scale | Standard Deviation 1.75 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Rapid Letter Naming | 0.24 units on a scale | Standard Deviation 1.64 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Rapid Naming | 0.35 units on a scale | Standard Deviation 9.75 |
| ADHD Alone: Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Memory for Digits | -0.50 units on a scale | Standard Deviation 1.9 |
| ADHD Alone: Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Blending Words | 1.86 units on a scale | Standard Deviation 1.86 |
| ADHD Alone: Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Rapid Digit Naming | 0.23 units on a scale | Standard Deviation 1.23 |
| ADHD Alone: Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Elision | 0.27 units on a scale | Standard Deviation 1.91 |
| ADHD Alone: Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Rapid Naming | -0.59 units on a scale | Standard Deviation 10.83 |
| ADHD Alone: Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Phonological Awareness | 6.82 units on a scale | Standard Deviation 11.5 |
| ADHD Alone: Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Non-word Repetition | 0.82 units on a scale | Standard Deviation 2.52 |
| ADHD Alone: Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Rapid Letter Naming | 0.14 units on a scale | Standard Deviation 1.52 |
| ADHD Alone: Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 16 Endpoint | Phonological Memory | 1.36 units on a scale | Standard Deviation 11.33 |
Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint
The CTOPP assesses phonological awareness, phonological memory, and rapid naming and is appropriate for ages 7 to 24. The test contains six core subtests. The composite scores are 1) Phonological Awareness, comprised of the standard scores of the Elision and Blending Words; 2) Phonological Memory, comprised of standard scores for Memory for Digits and Non-word Repetition; and 3) Rapid Naming, comprised of standard scores for Rapid Digit Naming and Rapid Letter Naming. Standard scores range from 1-20, and composite scores range from 35-165. Higher scores are better.
Time frame: Baseline, 32 weeks
Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Blending Words | 1.31 units on a scale | Standard Deviation 2.01 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Elision | 1.07 units on a scale | Standard Deviation 2 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Memory for Digits | 0.87 units on a scale | Standard Deviation 2.17 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Non-word Repetition | 0.93 units on a scale | Standard Deviation 2.27 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Phonological Awareness | 7.33 units on a scale | Standard Deviation 9.5 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Phonological Memory | 4.93 units on a scale | Standard Deviation 10.57 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Rapid Digit Naming | 0.43 units on a scale | Standard Deviation 1.91 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Rapid Letter Naming | 0.43 units on a scale | Standard Deviation 2.06 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Rapid Naming | 1.30 units on a scale | Standard Deviation 11.27 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Rapid Letter Naming | 0.90 units on a scale | Standard Deviation 2.34 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Blending Words | 1.90 units on a scale | Standard Deviation 2.98 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Phonological Memory | -0.67 units on a scale | Standard Deviation 12.44 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Elision | 0.71 units on a scale | Standard Deviation 3.05 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Non-word Repetition | 0.43 units on a scale | Standard Deviation 3.03 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Memory for Digits | -0.05 units on a scale | Standard Deviation 2.13 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Rapid Digit Naming | 0.62 units on a scale | Standard Deviation 2.31 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Rapid Naming | 1.76 units on a scale | Standard Deviation 12.35 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Comprehensive Test of Phonological Processing (CTOPP) at Week 32 Endpoint | Phonological Awareness | 5.33 units on a scale | Standard Deviation 15.99 |
Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint
The GORT-4 is a norm-referenced test of oral reading rate, accuracy, fluency, and comprehension valid for individuals aged 6 to 18 years old. The test has two parallel forms, Form A and Form B, that are administered in an alternating fashion (e.g. Week 0-Form A, Week 16-Form B, Week 32-Form A.) with each containing 14 separate stories and 5 multiple-choice comprehension questions for each story. GORT-4 yields the following scores: rate, accuracy, fluency, comprehension, and overall reading ability. Standard scores range from 1-20. Higher scores indicate better reading skills.
Time frame: Baseline, 16 weeks
Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Oral Reading Quotient | -1.43 units on a scale | Standard Deviation 23.34 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Fluency Score | 0.78 units on a scale | Standard Deviation 2.81 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Accuracy Score | 0.71 units on a scale | Standard Deviation 2.22 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Comprehension Score | 0.37 units on a scale | Standard Deviation 2.35 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Rate Score | 0.20 units on a scale | Standard Deviation 1.65 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Fluency Score | 0.33 units on a scale | Standard Deviation 2.82 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Accuracy Score | 0.40 units on a scale | Standard Deviation 2.02 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Comprehension Score | 0.65 units on a scale | Standard Deviation 2.5 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Oral Reading Quotient | 2.87 units on a scale | Standard Deviation 20.43 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Rate Score | 0.05 units on a scale | Standard Deviation 1.54 |
| ADHD Alone: Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Rate Score | 0.38 units on a scale | Standard Deviation 2.27 |
| ADHD Alone: Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Oral Reading Quotient | 2.43 units on a scale | Standard Deviation 10.93 |
| ADHD Alone: Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Accuracy Score | 0.95 units on a scale | Standard Deviation 2.16 |
| ADHD Alone: Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Fluency Score | 1.14 units on a scale | Standard Deviation 2.94 |
| ADHD Alone: Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 16 Endpoint | Comprehension Score | -0.33 units on a scale | Standard Deviation 1.93 |
Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint
The GORT-4 is a norm-referenced test of oral reading rate, accuracy, fluency, and comprehension valid for individuals aged 6 to 18 years old. The test has two parallel forms, Form A and Form B, that are administered in an alternating fashion (e.g. Week 0-Form A, Week 16-Form B, Week 32-Form A.) with each containing 14 separate stories and 5 multiple-choice comprehension questions for each story. GORT-4 yields the following scores: rate, accuracy, fluency, comprehension, and overall reading ability. Standard scores range from 1-20. Higher scores indicate better reading skills.
Time frame: Baseline, 32 weeks
Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint | Comprehension Score | 0.04 units on a scale | Standard Deviation 1.73 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint | Oral Reading Quotient | 2.64 units on a scale | Standard Deviation 15.05 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint | Fluency Score | 0.76 units on a scale | Standard Deviation 1.4 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint | Rate Score | 0.58 units on a scale | Standard Deviation 1.74 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint | Accuracy Score | 0.82 units on a scale | Standard Deviation 1.3 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint | Rate Score | 0.15 units on a scale | Standard Deviation 1.98 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint | Accuracy Score | 0.95 units on a scale | Standard Deviation 1.82 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint | Comprehension Score | -0.30 units on a scale | Standard Deviation 1.59 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint | Fluency Score | 1.10 units on a scale | Standard Deviation 2.63 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Gray Oral Reading Test-4 (GORT-4) at Week 32 Endpoint | Oral Reading Quotient | -1.30 units on a scale | Standard Deviation 21.22 |
Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint
The K-SCT rating scale contains 3 components: Youth, Parent, and Teacher ratings. It queries 17 candidate SCT symptoms, such as daydreams, lost in a fog, sluggish/drowsy. Scores range from 0-51. Lower scores indicate less sluggish.
Time frame: Baseline, 16 weeks
Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint | Total Score-Teacher Variation (n= 22, 22, 11) | -8.82 units on a scale | Standard Deviation 11.77 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint | Total Score-Parent Variation (n= 56, 57, 23) | -7.82 units on a scale | Standard Deviation 10.98 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint | Total Score-Youth Variation (n= 56, 57, 23) | -4.71 units on a scale | Standard Deviation 9.27 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint | Total Score-Teacher Variation (n= 22, 22, 11) | -1.64 units on a scale | Standard Deviation 6.53 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint | Total Score-Parent Variation (n= 56, 57, 23) | -4.64 units on a scale | Standard Deviation 9.67 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint | Total Score-Youth Variation (n= 56, 57, 23) | -4.21 units on a scale | Standard Deviation 6.85 |
| ADHD Alone: Atomoxetine | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint | Total Score-Parent Variation (n= 56, 57, 23) | -8.24 units on a scale | Standard Deviation 9.9 |
| ADHD Alone: Atomoxetine | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint | Total Score-Youth Variation (n= 56, 57, 23) | -6.17 units on a scale | Standard Deviation 7.71 |
| ADHD Alone: Atomoxetine | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 16 Endpoint | Total Score-Teacher Variation (n= 22, 22, 11) | -3.47 units on a scale | Standard Deviation 8.83 |
Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 Endpoint
The K-SCT rating scale contains 3 components: Youth, Parent, and Teacher ratings. It queries 17 candidate SCT symptoms, such as daydreams, lost in a fog, sluggish/drowsy. Scores range from 0-51. Lower scores indicate less sluggish.
Time frame: Baseline, 32 weeks
Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 Endpoint | Total Score-Parent Variation (n=45, 21) | -10.40 units on a scale | Standard Deviation 11.94 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 Endpoint | Total Score-Teacher Variation (n=23, 9) | -7.00 units on a scale | Standard Deviation 12.82 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 Endpoint | Total Score-Youth Variation (n=45, 21) | -4.36 units on a scale | Standard Deviation 7.57 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 Endpoint | Total Score-Parent Variation (n=45, 21) | -10.83 units on a scale | Standard Deviation 10.84 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 Endpoint | Total Score-Teacher Variation (n=23, 9) | -7.89 units on a scale | Standard Deviation 5.18 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Kiddie Sluggish Cognitive Tempo (K-SCT) at Week 32 Endpoint | Total Score-Youth Variation (n=45, 21) | -5.43 units on a scale | Standard Deviation 8.44 |
Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint
LPS-C is a short (24 item, 0-3 points per item) parent-rated scale that is designed to assess changes in adaptive functioning related to treatment for ADHD. This scale measures improvements in social, emotional, cognitive, educational, and affiliative (family, friends) functioning, which indirectly reflect improvements in executive functioning. Happy/social subscores range from 0-18, and self-control subscores range from 0-54. Total scores range from 0-72. Higher scores are better for LPS.
Time frame: Baseline, 16 weeks
Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint | LPS Self Control Score | 6.06 units on a scale | Standard Deviation 8.54 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint | LPS Happy/Social Score | 0.57 units on a scale | Standard Deviation 4.19 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint | LPS Total Score | 6.51 units on a scale | Standard Deviation 11.61 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint | LPS Self Control Score | 4.29 units on a scale | Standard Deviation 10.6 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint | LPS Happy/Social Score | 0.53 units on a scale | Standard Deviation 4.8 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint | LPS Total Score | 4.82 units on a scale | Standard Deviation 14.2 |
| ADHD Alone: Atomoxetine | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint | LPS Happy/Social Score | 1.38 units on a scale | Standard Deviation 3.73 |
| ADHD Alone: Atomoxetine | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint | LPS Total Score | 9.05 units on a scale | Standard Deviation 10.63 |
| ADHD Alone: Atomoxetine | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 16 Endpoint | LPS Self Control Score | 7.49 units on a scale | Standard Deviation 8.46 |
Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 Endpoint
LPS-C is a short (24 item, 0-3 points per item) parent-rated scale that is designed to assess changes in adaptive functioning related to treatment for ADHD. This scale measures improvements in social, emotional, cognitive, educational, and affiliative (family, friends) functioning, which indirectly reflect improvements in executive functioning. Happy/social subscores range from 0-18, and self-control subscores range from 0-54. Total scores range from 0-72. Higher scores are better for LPS.
Time frame: Baseline, 32 weeks
Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 Endpoint | LPS Happy/Social Score (n=45, 21) | 1.57 units on a scale | Standard Deviation 4.37 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 Endpoint | LPS Self Control Score (n=45, 20) | 9.10 units on a scale | Standard Deviation 10.73 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 Endpoint | LPS Total Score (n=45, 20) | 10.67 units on a scale | Standard Deviation 14.27 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 Endpoint | LPS Happy/Social Score (n=45, 21) | 2.14 units on a scale | Standard Deviation 4.3 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 Endpoint | LPS Self Control Score (n=45, 20) | 10.44 units on a scale | Standard Deviation 10.42 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Life Participation Scale-child (LPS-C) Score at Week 32 Endpoint | LPS Total Score (n=45, 20) | 12.64 units on a scale | Standard Deviation 13.95 |
Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint
The MSCS is an overall assessment of self concept or an individual measure of any of the six scaled dimensions of self concept: Social, Competence, Affect, Academic, Family, and Physical. Standard scores range from 45-145. Higher scores are better (indicate higher self concept).
Time frame: Baseline, 16 weeks
Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Affect Standard Section Score | 3.62 units on a scale | Standard Deviation 10.32 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Social Standard Section Score | 4.36 units on a scale | Standard Deviation 11.73 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Family Standard Section Score | 0.39 units on a scale | Standard Deviation 12.52 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Academic Standard Section Score | 5.91 units on a scale | Standard Deviation 9.01 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Physical Standard Section Score | 4.09 units on a scale | Standard Deviation 10.34 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Standard Total Score | 4.72 units on a scale | Standard Deviation 9.47 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Competence Standard Section Score | 6.64 units on a scale | Standard Deviation 12.99 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Physical Standard Section Score | 1.32 units on a scale | Standard Deviation 12.06 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Academic Standard Section Score | 4.23 units on a scale | Standard Deviation 12.77 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Affect Standard Section Score | 2.35 units on a scale | Standard Deviation 10.81 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Competence Standard Section Score | 4.95 units on a scale | Standard Deviation 12.05 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Family Standard Section Score | -3.12 units on a scale | Standard Deviation 11.66 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Social Standard Section Score | 2.72 units on a scale | Standard Deviation 11.14 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Standard Total Score | 1.98 units on a scale | Standard Deviation 10.19 |
| ADHD Alone: Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Competence Standard Section Score | 5.20 units on a scale | Standard Deviation 9.06 |
| ADHD Alone: Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Standard Total Score | 3.44 units on a scale | Standard Deviation 7.7 |
| ADHD Alone: Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Social Standard Section Score | 3.88 units on a scale | Standard Deviation 10.39 |
| ADHD Alone: Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Affect Standard Section Score | 3.56 units on a scale | Standard Deviation 10.58 |
| ADHD Alone: Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Academic Standard Section Score | 5.52 units on a scale | Standard Deviation 6.78 |
| ADHD Alone: Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Family Standard Section Score | -1.00 units on a scale | Standard Deviation 12.26 |
| ADHD Alone: Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 16 Endpoint | Physical Standard Section Score | 3.04 units on a scale | Standard Deviation 5.99 |
Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint
The MSCS is an overall assessment of self concept or an individual measure of any of the six scaled dimensions of self concept: Social, Competence, Affect, Academic, Family, and Physical. Standard scores range from 45-145. Higher scores are better (indicate higher self concept).
Time frame: Baseline, 32 weeks
Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Competence Standard Section Score | 6.76 units on a scale | Standard Deviation 11.77 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Physical Standard Section Score | 6.09 units on a scale | Standard Deviation 12 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Affect Standard Section Score | 4.29 units on a scale | Standard Deviation 11.14 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Social Standard Section Score | 4.84 units on a scale | Standard Deviation 11.84 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Family Standard Section Score | 0.16 units on a scale | Standard Deviation 14.4 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Standard Total Score | 5.61 units on a scale | Standard Deviation 10.82 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Academic Standard Section Score | 6.02 units on a scale | Standard Deviation 9.72 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Standard Total Score | 3.48 units on a scale | Standard Deviation 7.21 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Academic Standard Section Score | 5.43 units on a scale | Standard Deviation 6.98 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Affect Standard Section Score | 3.14 units on a scale | Standard Deviation 10.45 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Competence Standard Section Score | 5.19 units on a scale | Standard Deviation 7.94 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Family Standard Section Score | 0.33 units on a scale | Standard Deviation 9.79 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Physical Standard Section Score | 2.43 units on a scale | Standard Deviation 7.2 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Multidimensional Self Concept Scale (MSCS) at Week 32 Endpoint | Social Standard Section Score | 2.38 units on a scale | Standard Deviation 11.75 |
Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint
The TOWRE is a measure of an individual's ability to pronounce printed words accurately and fluently and is appropriate for individuals aged 6 to 24 years old. The TOWRE contains two subtests: Sight Word Efficiency (SWE) which assesses the number of real printed words that can be accurately identified within 45 seconds and Phonemic Decoding Efficiency (PDE) which measures the number of pronounceable printed non-words that can be accurately decoded within 45 seconds. Scores range from 45-146. Higher scores indicate higher reading proficiency.
Time frame: Baseline, 16 weeks
Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint | Sight Word Efficiency | 1.38 units on a scale | Standard Deviation 5.78 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint | Phonemic Decoding Efficiency | 1.92 units on a scale | Standard Deviation 6.01 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint | Total Word Reading Efficiency Standard Score | -0.57 units on a scale | Standard Deviation 21.98 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint | Sight Word Efficiency | 1.19 units on a scale | Standard Deviation 4.8 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint | Phonemic Decoding Efficiency | 1.21 units on a scale | Standard Deviation 5.19 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint | Total Word Reading Efficiency Standard Score | 2.81 units on a scale | Standard Deviation 11.9 |
| ADHD Alone: Atomoxetine | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint | Phonemic Decoding Efficiency | 1.77 units on a scale | Standard Deviation 6.78 |
| ADHD Alone: Atomoxetine | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint | Total Word Reading Efficiency Standard Score | -5.88 units on a scale | Standard Deviation 25.98 |
| ADHD Alone: Atomoxetine | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 16 Endpoint | Sight Word Efficiency | 0.69 units on a scale | Standard Deviation 8.84 |
Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 Endpoint
The TOWRE is a measure of an individual's ability to pronounce printed words accurately and fluently and is appropriate for individuals aged 6 to 24 years old. The TOWRE contains two subtests: Sight Word Efficiency (SWE) which assesses the number of real printed words that can be accurately identified within 45 seconds and Phonemic Decoding Efficiency (PDE) which measures the number of pronounceable printed non-words that can be accurately decoded within 45 seconds. Scores range from 45-146. Higher scores indicate higher reading proficiency.
Time frame: Baseline, 32 weeks
Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 Endpoint | Phonemic Decoding Efficiency | 2.64 units on a scale | Standard Deviation 6.54 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 Endpoint | Sight Word Efficiency | 1.93 units on a scale | Standard Deviation 6.51 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 Endpoint | Total Word Reading Efficiency Standard Score | 2.56 units on a scale | Standard Deviation 17.35 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 Endpoint | Phonemic Decoding Efficiency | 5.33 units on a scale | Standard Deviation 6.98 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 Endpoint | Sight Word Efficiency | 4.62 units on a scale | Standard Deviation 8.74 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Test of Word Reading Efficiency (TOWRE) at Week 32 Endpoint | Total Word Reading Efficiency Standard Score | 1.52 units on a scale | Standard Deviation 20.64 |
Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint
The Woodcock Johnson Tests of Achievement has a Standard Battery (Tests 1-12) of a broad set of scores and an Extended Battery (Tests 13-22) on specific academic strengths and weaknesses. Tests associated with reading skills (1, 2, 7, 9, 13, 17, 20) were administered. Scores for each individual test can range from 0 to over 200 where anything 69 and below is very low and anything 131 and above is very superior. Higher scores indicate better reading skills.
Time frame: Baseline, 16 weeks
Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Reading Comprehension (Test 9, 17) | -0.08 units on a scale | Standard Deviation 9.68 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Word Attack (Test 13) | 2.27 units on a scale | Standard Deviation 6.75 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Reading Vocabulary (Test 17) | 0.51 units on a scale | Standard Deviation 8.92 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Reading Fluency (Test 2) | -0.24 units on a scale | Standard Deviation 7.91 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Basic Reading Skills (Tests 1, 13) | 1.75 units on a scale | Standard Deviation 6.04 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Spelling of Sounds (Test 20) | 5.67 units on a scale | Standard Deviation 16.07 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Passage Comprehension (Test 9) | -0.92 units on a scale | Standard Deviation 11.43 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Letter-Word Identification (Test 1) | 1.18 units on a scale | Standard Deviation 7.2 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Spelling (Test 7) | -0.22 units on a scale | Standard Deviation 7.32 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Reading Fluency (Test 2) | -0.11 units on a scale | Standard Deviation 9.19 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Basic Reading Skills (Tests 1, 13) | 0.87 units on a scale | Standard Deviation 6.75 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Letter-Word Identification (Test 1) | -0.07 units on a scale | Standard Deviation 6.63 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Passage Comprehension (Test 9) | -1.02 units on a scale | Standard Deviation 8.94 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Reading Comprehension (Test 9, 17) | -1.09 units on a scale | Standard Deviation 8.81 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Reading Vocabulary (Test 17) | -0.16 units on a scale | Standard Deviation 9.45 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Spelling (Test 7) | -4.16 units on a scale | Standard Deviation 12.13 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Spelling of Sounds (Test 20) | 3.31 units on a scale | Standard Deviation 13.49 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Word Attack (Test 13) | 1.13 units on a scale | Standard Deviation 9.75 |
| ADHD Alone: Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Passage Comprehension (Test 9) | -4.50 units on a scale | Standard Deviation 9.04 |
| ADHD Alone: Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Basic Reading Skills (Tests 1, 13) | -0.41 units on a scale | Standard Deviation 7.99 |
| ADHD Alone: Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Spelling (Test 7) | -0.41 units on a scale | Standard Deviation 5.68 |
| ADHD Alone: Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Letter-Word Identification (Test 1) | -0.32 units on a scale | Standard Deviation 8.04 |
| ADHD Alone: Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Word Attack (Test 13) | -0.36 units on a scale | Standard Deviation 7.88 |
| ADHD Alone: Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Reading Fluency (Test 2) | 1.36 units on a scale | Standard Deviation 8.77 |
| ADHD Alone: Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Reading Comprehension (Test 9, 17) | -5.00 units on a scale | Standard Deviation 7.45 |
| ADHD Alone: Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Spelling of Sounds (Test 20) | 8.45 units on a scale | Standard Deviation 19.78 |
| ADHD Alone: Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 16 Endpoint | Reading Vocabulary (Test 17) | -3.95 units on a scale | Standard Deviation 8.6 |
Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint
The Woodcock Johnson Tests of Achievement has a Standard Battery (Tests 1-12) of a broad set of scores and an Extended Battery (Tests 13-22) on specific academic strengths and weaknesses. Tests associated with reading skills (1, 2, 7, 9, 13, 17, 20) were administered. Scores for each individual test can range from 0 to over 200 where anything 69 and below is very low and anything 131 and above is very superior. Higher scores indicate better reading skills.
Time frame: Baseline, 32 weeks
Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Letter-Word Identification (Test 1) | 1.69 units on a scale | Standard Deviation 7.19 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Reading Vocabulary (Test 17) | 2.60 units on a scale | Standard Deviation 8.55 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Reading Comprehension (Tests 9, 17) | 2.89 units on a scale | Standard Deviation 9.07 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Spelling (Test 7) | 0.60 units on a scale | Standard Deviation 7.74 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Passage Comprehension (Test 9) | 2.31 units on a scale | Standard Deviation 9.18 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Spelling of Sounds (Test 20) | 2.98 units on a scale | Standard Deviation 10.77 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Reading Fluency (Test 2) | 2.69 units on a scale | Standard Deviation 9.04 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Word Attack (Test 13) | 3.27 units on a scale | Standard Deviation 7.09 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Basic Reading Skills (Tests 1, 13 | 2.73 units on a scale | Standard Deviation 6.51 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Word Attack (Test 13) | -0.90 units on a scale | Standard Deviation 6.59 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Basic Reading Skills (Tests 1, 13 | -0.24 units on a scale | Standard Deviation 5.37 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Letter-Word Identification (Test 1) | 0.24 units on a scale | Standard Deviation 5.73 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Passage Comprehension (Test 9) | 1.24 units on a scale | Standard Deviation 5.63 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Reading Comprehension (Tests 9, 17) | 0.86 units on a scale | Standard Deviation 7.04 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Reading Fluency (Test 2) | 3.24 units on a scale | Standard Deviation 8.64 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Reading Vocabulary (Test 17) | -0.14 units on a scale | Standard Deviation 10.57 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Spelling (Test 7) | 0.38 units on a scale | Standard Deviation 5.96 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Woodcock-Johnson III Scores at Week 32 Endpoint | Spelling of Sounds (Test 20) | 5.90 units on a scale | Standard Deviation 14.17 |
Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint
WMTB-C is assessment of working memory capacities, consisting of 9 subtests (Trials Correct Scores \[Range from 55-145\], Higher scores are better) reflecting 3 main components of working memory: central executive (CE) control/regulation of working memory (Backward Digit Recall, Listening Recall, Counting Recall); phonological loop (PL) responsible for holding verbal information for short periods (Digit Recall, Word List Matching, Word List Recall, Non-word List Recall); and visuo-spatial sketchpad (VSSP) which holds information in visual and spatial form (Block Recall, Mazes Memory).
Time frame: Baseline, 16 weeks
Population: All randomized participants with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Word List Matching (n=54, 56, 23) | -0.20 units on a scale | Standard Deviation 7.08 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Counting Recall (n=54, 56, 23) | 0.50 units on a scale | Standard Deviation 4.63 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Block Recall (n=54, 56, 23) | -0.37 units on a scale | Standard Deviation 4.2 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Word List Recall (n=54, 56, 23) | 1.00 units on a scale | Standard Deviation 3.29 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Visuo-Spatial Sketchpad Score (n=47, 43, 21) | 4.15 units on a scale | Standard Deviation 11.96 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Non-Word List Recall (n=53, 56, 23) | 0.89 units on a scale | Standard Deviation 2.74 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Phonological Loop Component Score (n=51, 54, 21) | 3.57 units on a scale | Standard Deviation 10.79 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Central Executive Component Score (n=41, 44,12) | 7.34 units on a scale | Standard Deviation 10.65 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Listening Recall (n=54, 56, 23) | 1.52 units on a scale | Standard Deviation 3.32 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Digit Recall (n=54, 56, 23) | 0.17 units on a scale | Standard Deviation 3.42 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Backward Digit Recall (n=54, 56, 23) | 1.30 units on a scale | Standard Deviation 3.87 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Mazes Memory (n=54, 56, 23) | 1.94 units on a scale | Standard Deviation 5.9 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Non-Word List Recall (n=53, 56, 23) | 0.71 units on a scale | Standard Deviation 2.2 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Phonological Loop Component Score (n=51, 54, 21) | 1.63 units on a scale | Standard Deviation 9 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Central Executive Component Score (n=41, 44,12) | -0.89 units on a scale | Standard Deviation 13.65 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Visuo-Spatial Sketchpad Score (n=47, 43, 21) | -0.47 units on a scale | Standard Deviation 12.85 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Digit Recall (n=54, 56, 23) | 0.55 units on a scale | Standard Deviation 3.01 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Word List Matching (n=54, 56, 23) | 0.05 units on a scale | Standard Deviation 8.65 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Word List Recall (n=54, 56, 23) | 0.02 units on a scale | Standard Deviation 3.15 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Block Recall (n=54, 56, 23) | -0.80 units on a scale | Standard Deviation 4.18 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Mazes Memory (n=54, 56, 23) | 1.18 units on a scale | Standard Deviation 5.94 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Listening Recall (n=54, 56, 23) | 1.00 units on a scale | Standard Deviation 3.77 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Counting Recall (n=54, 56, 23) | 0.45 units on a scale | Standard Deviation 5.07 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Backward Digit Recall (n=54, 56, 23) | 0.16 units on a scale | Standard Deviation 3.62 |
| ADHD Alone: Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Phonological Loop Component Score (n=51, 54, 21) | 2.24 units on a scale | Standard Deviation 9.78 |
| ADHD Alone: Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Mazes Memory (n=54, 56, 23) | 0.78 units on a scale | Standard Deviation 7.33 |
| ADHD Alone: Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Visuo-Spatial Sketchpad Score (n=47, 43, 21) | 3.67 units on a scale | Standard Deviation 10.77 |
| ADHD Alone: Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Word List Recall (n=54, 56, 23) | 0.35 units on a scale | Standard Deviation 2.98 |
| ADHD Alone: Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Listening Recall (n=54, 56, 23) | 0.04 units on a scale | Standard Deviation 5.9 |
| ADHD Alone: Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Central Executive Component Score (n=41, 44,12) | 2.17 units on a scale | Standard Deviation 11.77 |
| ADHD Alone: Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Backward Digit Recall (n=54, 56, 23) | 1.26 units on a scale | Standard Deviation 4.2 |
| ADHD Alone: Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Non-Word List Recall (n=53, 56, 23) | 0.43 units on a scale | Standard Deviation 3.53 |
| ADHD Alone: Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Word List Matching (n=54, 56, 23) | 2.04 units on a scale | Standard Deviation 9.24 |
| ADHD Alone: Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Counting Recall (n=54, 56, 23) | 0.48 units on a scale | Standard Deviation 5.41 |
| ADHD Alone: Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Block Recall (n=54, 56, 23) | 0.70 units on a scale | Standard Deviation 4.24 |
| ADHD Alone: Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 16 Endpoint | Digit Recall (n=54, 56, 23) | 0.22 units on a scale | Standard Deviation 4.45 |
Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint
WMTB-C is assessment of working memory capacities, consisting of 9 subtests (Trials Correct Scores \[Range from 55-145\], Higher scores are better) reflecting 3 main components of working memory: central executive (CE) control/regulation of working memory (Backward Digit Recall, Listening Recall, Counting Recall); phonological loop (PL) responsible for holding verbal information for short periods (Digit Recall, Word List Matching, Word List Recall, Non-word List Recall); and visuo-spatial sketchpad (VSSP) which holds information in visual and spatial form (Block Recall, Mazes Memory).
Time frame: Baseline, 32 weeks
Population: All randomized participants who entered open-label phase with a baseline and at least one post-baseline result, and last observation carried forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Digit Recall (n=45, 21) | -0.04 units on a scale | Standard Deviation 2.92 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Non-Word List Recall (n=44, 21) | 0.55 units on a scale | Standard Deviation 2.9 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Visuo-Spatial Sketchpad Component Score (n=40, 20) | 3.85 units on a scale | Standard Deviation 12.89 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Block Recall (n=45, 21) | 0.71 units on a scale | Standard Deviation 3.88 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Word List Matching (n=45, 21) | 2.38 units on a scale | Standard Deviation 7.96 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Mazes Memory (n=45, 21) | 2.33 units on a scale | Standard Deviation 7.04 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Backward Digit Recall (n=45, 21) | 1.07 units on a scale | Standard Deviation 3.24 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Listening Recall (n=45, 21) | 2.18 units on a scale | Standard Deviation 4.01 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Central Executive Component Score (n=38, 14) | 6.53 units on a scale | Standard Deviation 11.34 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Counting Recall (n=45, 21) | 1.53 units on a scale | Standard Deviation 4.65 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Word List Recall (n=45, 21) | 1.49 units on a scale | Standard Deviation 3 |
| ADHD+ Dyslexia (D): Atomoxetine | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Phonological Loop Component Score (n=43, 20) | 3.67 units on a scale | Standard Deviation 11.27 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Backward Digit Recall (n=45, 21) | 2.29 units on a scale | Standard Deviation 5.2 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Phonological Loop Component Score (n=43, 20) | 1.70 units on a scale | Standard Deviation 9.66 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Central Executive Component Score (n=38, 14) | 1.64 units on a scale | Standard Deviation 11.3 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Visuo-Spatial Sketchpad Component Score (n=40, 20) | 2.65 units on a scale | Standard Deviation 9.96 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Digit Recall (n=45, 21) | 0.52 units on a scale | Standard Deviation 4.08 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Word List Matching (n=45, 21) | 1.95 units on a scale | Standard Deviation 8.22 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Word List Recall (n=45, 21) | 0.33 units on a scale | Standard Deviation 2.5 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Non-Word List Recall (n=44, 21) | -0.67 units on a scale | Standard Deviation 4.39 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Block Recall (n=45, 21) | 1.05 units on a scale | Standard Deviation 4.24 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Mazes Memory (n=45, 21) | 3.48 units on a scale | Standard Deviation 7.77 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Listening Recall (n=45, 21) | -1.05 units on a scale | Standard Deviation 6.42 |
| ADHD+ Dyslexia (D): Placebo | Change From Baseline in Working Memory Test Battery for Children (WMTB-C) at Week 32 Endpoint | Counting Recall (n=45, 21) | 1.24 units on a scale | Standard Deviation 6.54 |